At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ETNB 89Bio, Inc.
Closed 05-28 16:00:00 EDT
8.32
+0.18
+2.21%
盘后8.46
+0.14+1.68%
19:11 EDT
High8.41Low7.93Vol817.33K
Open8.32D1 Closing8.14Amplitude5.90%
Mkt Cap818.55MTradable Cap580.71MTotal Shares98.38M
T/O6.72MT/O Rate1.17%Tradable Shares69.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Altimmune: A Potential Minor Player In The Massive GLP-1 Space
seekingalpha  ·  05:45
Altimmune: A Potential Minor Player In The Massive GLP-1 Space
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
seekingalpha  ·  05-23
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
GlobeNewswire  ·  05-23
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
RBC Capital Remains a Hold on 89bio (ETNB)
TIPRANKS  ·  05-17
RBC Capital Remains a Hold on 89bio (ETNB)
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Ionis Pharmaceuticals (IONS) and 89bio (ETNB)
TIPRANKS  ·  05-17
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Ionis Pharmaceuticals (IONS) and 89bio (ETNB)
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Celcuity (CELC) and 89bio (ETNB)
TIPRANKS  ·  05-16
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Celcuity (CELC) and 89bio (ETNB)
BRIEF-89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis
Reuters  ·  05-14
BRIEF-89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis
Cantor picks 14 undervalued biotech stocks worth a second look
seekingalpha  ·  05-12
Cantor picks 14 undervalued biotech stocks worth a second look
BRIEF-89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  05-11
BRIEF-89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
89bio GAAP EPS of -$0.54 misses by $0.07
seekingalpha  ·  05-10
89bio GAAP EPS of -$0.54 misses by $0.07
89bio Q1 2024 GAAP EPS $(0.54) Misses $(0.46) Estimate
Benzinga  ·  05-10
89bio Q1 2024 GAAP EPS $(0.54) Misses $(0.46) Estimate
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire  ·  05-10
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
89bio to Participate in the BofA Securities 2024 Health Care Conference
GlobeNewswire  ·  05-09
89bio to Participate in the BofA Securities 2024 Health Care Conference
89Bio Inc expected to post a loss of 46 cents a share - Earnings Preview
Reuters  ·  04-30
89Bio Inc expected to post a loss of 46 cents a share - Earnings Preview
3 Potential Biopharma Buyout Targets
seekingalpha  ·  04-24
3 Potential Biopharma Buyout Targets
Hepion ends Phase 2 study for NASH drug due to cash restraints
seekingalpha  ·  04-20
Hepion ends Phase 2 study for NASH drug due to cash restraints
BRIEF-89bio Appoints Biotech Industry Veteran, Martin Babler To Its Board Of Directors
Reuters  ·  04-18
BRIEF-89bio Appoints Biotech Industry Veteran, Martin Babler To Its Board Of Directors
89bio Enhances Board with Biopharma Veteran Martin Babler
TIPRANKS  ·  04-18
89bio Enhances Board with Biopharma Veteran Martin Babler
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
GlobeNewswire  ·  04-18
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

Introduction

Company Name.
89Bio, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Issue price:
--